Ruxolitinib, a small molecule inhibitor of JAK1 and JAK2 kinases, has been approved by the FDA for the treatment of polycythemia vera and intermediate to high-risk myelofibrosis. The gene discussed is JAK1; the disease is myelofibrosis.